Table 2.
Thyroid functions and treatment given to the patient subsequent to the pandemic and post mRNA COVID vaccination with rising tide of TRAb titres.
| Mar 2020 | Mar 2021 | Apr 2021 | May 2021 | Sep 2021 | Dec 2021 | Aug 2022 | Dec 2022 | May 2023 | Jun 2023 | Mar 2024 | Apr 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TSH (0.3–5) mIU/L | 0.17 | - | - | – | 3.77 | 1.81 | 2 | 0.32 | 16.15 | 1.49 | 1.24 | 1.09 |
| Free T4 (8- 19) pmol/ L | 20 | - | - | 12 | 15 | 15 | 18 | 12 | - | - | 13.5 | |
| Free T3 (2.1–6) pmol/L | - | - | - | - | - | - | - | - | - | - | - | - |
| TRAb (0.0-0.9 IU/L) | - | - | - | - | 45.2 | 37.8 | 37.6 | - | - | - | 118.1 | |
| Treatment | Levothyroxine 75/100 mcg consistently with no change to the dose at any stage | |||||||||||
| Intervention/event | COVID Vaccine 1 | Eye symptoms develop | COVID Vaccine 2 | |||||||||